Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: Analysis of a large United States claims database

Clinical Therapeutics

Volumn 23, Issue 12, 2001, Pages 1984-1998

  Schnitzer, Thomas J ^a   Kong, Sheldon X ^b   Mavros, Panagiotis ^b   Straus, Walter L ^b   Watson, Douglas J ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Gastroprotective agents; Misoprostol; Nonsteroidal anti inflammatory drugs; Prescription patterns; Proton pump inhibitors

Indexed keywords

ARTHROTEC; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DATA BASE; DRUG INDUCED DISEASE; DRUG USE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PRESCRIPTION; STOMACH PROTECTION; UNITED STATES;

EID: 0035692914     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80151-X     Document Type: Article

References (29)

1. The mode of action of aspirin-like drugs
2. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
3. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
4. Epidemiology of NSAID induced gastrointestinal complications
5. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy
6. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use
7. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
8. Ulcer complications and nonsteroidal anti-inflammatory drugs
9. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
10. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
11. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
12. Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs
13. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease
14. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial
15. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs
16. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs
17. The risk of dyspepsia and serious gastrointestinal complications from nonsteroidal anti-inflammatory drugs: A meta-analysis
18. The clinical management of rheumatoid arthritis and osteoarthritis: Strategies for improving clinical effectiveness
19. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 Update
20. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients
21. Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs
22. Concomitant use of gastroprotective agents among users of nonsteroidal antiinflammatory drugs in Italy
23. Use of gastroprotective agents and other healthcare resources among patients on nonsteroidal anti-inflammatory drugs in the United Kingdom
24. Use of gastrointestinal (GI) protective agents among patients on non-steroidal antiinflammatory drugs in France
25. The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis
26. Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care
27. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
28. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis